Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Mayo Clinic
Mayo Clinic
Essen Biotech
University of California, San Diego
University of Iowa
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Wake Forest University Health Sciences
University of Oklahoma
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
University of California, San Diego
Royal Marsden NHS Foundation Trust
Masonic Cancer Center, University of Minnesota
University of Wisconsin, Madison
Memorial Sloan Kettering Cancer Center
University of Chicago
Institut Curie
University of Kentucky
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of California, San Diego
Memorial Sloan Kettering Cancer Center
The University of Texas Health Science Center, Houston
NYU Langone Health
NuCana plc
University of Wisconsin, Madison
Bank of Cyprus Oncology Centre
M.D. Anderson Cancer Center
Providence Health & Services
Fred Hutchinson Cancer Center
UNICANCER
University of Colorado, Denver
ImmunSYS, LLC
University of California, Davis
University of California, San Francisco
Queen Mary University of London
OHSU Knight Cancer Institute
Augusta University
Rutgers, The State University of New Jersey
Providence Health & Services
Valley Health System
Fondazione del Piemonte per l'Oncologia
University of Erlangen-Nürnberg Medical School
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Columbia University
M.D. Anderson Cancer Center